{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.groupedQuestionUIN=222037&max-answer.questionFirstAnswered.=2019-03-12T17%3A55%3A51.41Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?answer.groupedQuestionUIN=222037&max-answer.questionFirstAnswered.=2019-03-12T17%3A55%3A51.41Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.groupedQuestionUIN=222037&_metadata=all&max-answer.questionFirstAnswered.=2019-03-12T17%3A55%3A51.41Z", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&answer.groupedQuestionUIN=222037&max-answer.questionFirstAnswered.=2019-03-12T17%3A55%3A51.41Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.groupedQuestionUIN=222037&max-answer.questionFirstAnswered.=2019-03-12T17%3A55%3A51.41Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.groupedQuestionUIN=222037&max-answer.questionFirstAnswered.=2019-03-12T17%3A55%3A51.41Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1062114", "AnsweringBody" : [{"_value" : "Department for Work and Pensions"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1062114/answer", "answerText" : {"_value" : "<p>The Department does not require owners of limited companies to provide company financial accounts when applying for Universal Credit. Self-employed earnings are reported on a simplified 'cash accounting' basis, which asks for the total income from receipts into the business and details of payments out of the business under defined categories during the assessment period. The requirements were designed to be as simple as possible in order for self-employed claimants to easily report their earnings.<\/p><p> <\/p><p>The Department has therefore not made an assessment.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4014", "label" : {"_value" : "Biography information for Sir Alok Sharma"}
        }
        , "answeringMemberConstituency" : {"_value" : "Reading West"}
        , "answeringMemberPrinted" : {"_value" : "Alok Sharma"}
        , "dateOfAnswer" : {"_value" : "2019-02-20", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "222037"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-02-20T17:36:18.823Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "29"}
      , "answeringDeptShortName" : {"_value" : "Work and Pensions"}
      , "answeringDeptSortName" : {"_value" : "Work and Pensions"}
      , "date" : {"_value" : "2019-02-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Universal Credit"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Work and Pensions, for what reason her Department requires owners of limited companies to provide company financial accounts when applying for universal credit; and if she will review that policy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4440", "label" : {"_value" : "Biography information for Marion Fellows"}
      }
      , "tablingMemberConstituency" : {"_value" : "Motherwell and Wishaw"}
      , "tablingMemberPrinted" : [{"_value" : "Marion Fellows"}
      ], "uin" : "222036"}
    , {"_about" : "http://data.parliament.uk/resources/175736", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/175736/answer", "answerText" : {"_value" : "<p>Translarna (ataluren) was given conditional approval for the treatment of Duchenne Muscular Dystrophy by the European Medicines Agency in August 2014.<\/p><p> <\/p><p> <\/p><p> <\/p><p>NHS England is responsible for commissioning treatments for specialised services.<\/p><p> <\/p><p> <\/p><p> <\/p><p>At its Board meeting on 17 December, NHS England decided that the consultation on prioritisation for specialised services should be 90 days. The length of the consultation period reflects the importance of these decisions and advice received from patient groups. Decisions on prioritisation, including the advice from the Clinical Priorities Advisory Group on the routine commissioning of Translarna (ataluren), will not be completed until the consultation has closed and the consultation responses have had due consideration. NHS England launched the consultation on 27 January 2015 and it is open for responses until 27 April 2015.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Any prioritisation which is urgent on clinical grounds will continue to be dealt with quickly through NHS England\u2019s existing procedures. The route of individual funding requests remains the same.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2015-02-02", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "222037"}
        , {"_value" : "222038"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-02-02T16:35:40.17Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-01-26", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Muscular Dystrophy: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, whether the Government plans to commission Translarna during NHS England's public consultations on its principles and approach to decision making on drug licensing.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1486", "label" : {"_value" : "Biography information for Mr David Anderson"}
      }
      , "tablingMemberConstituency" : {"_value" : "Blaydon"}
      , "tablingMemberPrinted" : [{"_value" : "Mr David Anderson"}
      ], "uin" : "222036"}
    , {"_about" : "http://data.parliament.uk/resources/175740", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/175740/answer", "answerText" : {"_value" : "<p>Translarna (ataluren) was given conditional approval for the treatment of Duchenne Muscular Dystrophy by the European Medicines Agency in August 2014.<\/p><p> <\/p><p> <\/p><p> <\/p><p>NHS England is responsible for commissioning treatments for specialised services.<\/p><p> <\/p><p> <\/p><p> <\/p><p>At its Board meeting on 17 December, NHS England decided that the consultation on prioritisation for specialised services should be 90 days. The length of the consultation period reflects the importance of these decisions and advice received from patient groups. Decisions on prioritisation, including the advice from the Clinical Priorities Advisory Group on the routine commissioning of Translarna (ataluren), will not be completed until the consultation has closed and the consultation responses have had due consideration. NHS England launched the consultation on 27 January 2015 and it is open for responses until 27 April 2015.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Any prioritisation which is urgent on clinical grounds will continue to be dealt with quickly through NHS England\u2019s existing procedures. The route of individual funding requests remains the same.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2015-02-02", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "222036"}
        , {"_value" : "222037"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-02-02T16:35:40.073Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-01-26", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Drugs: Licensing"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, for how long NHS England's public consultations about the principles and approach to decision making on drug licensing will last.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1486", "label" : {"_value" : "Biography information for Mr David Anderson"}
      }
      , "tablingMemberConstituency" : {"_value" : "Blaydon"}
      , "tablingMemberPrinted" : [{"_value" : "Mr David Anderson"}
      ], "uin" : "222038"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 3, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}